FDA Begins New Safety Review of RSV Antibody Treatments for Infants
U.S. health regulators have launched a renewed safety examination of approved respiratory syncytial virus (RSV) preventive treatments for infants, according to sources familiar with the matter. Senior officials at pharmaceutical companies Merck, Sanofi, and AstraZeneca were informed last week that their RSV products would undergo additional scrutiny, despite already receiving regulatory approval. The therapies […]
Continue Reading